Carlton Humphries (llamaquit00)
Copyright © 2020 Zhijia Han et al.Unlike other tissue types, the nervous tissue extends to a wide and complex environment that provides a plurality of different biochemical and topological stimuli, which in turn defines the advanced functions of that tissue. As a consequence of such complexity, the traditional transplantation therapeutic methods are quite ineffective; therefore, the restoration of peripheral and central nervous system injuries has been a continuous scientific challenge. Tissue engineering and regenerative medicine in the nervous system have provided new alternative medical approaches. These methods use external biomaterial supports, known as scaffolds, to create platforms for the cells to migrate to the injury site and repair the tissue. The challenge in neural tissue engineering (NTE) remains the fabrication of scaffolds with precisely controlled, tunable topography, biochemical cues, and surface energy, capable of directing and controlling the function of neuronal cells toward the recovery from neurological disorders and injuries. At the same time, it has been shown that NTE provides the potential to model neurological diseases in vitro, mainly via lab-on-a-chip systems, especially in cases for which it is difficult to obtain suitable animal models. As a consequence of the intense research activity in the field, a variety of synthetic approaches and 3D fabrication methods have been developed for the fabrication of NTE scaffolds, including soft lithography and self-assembly, as well as subtractive (top-down) and additive (bottom-up) manufacturing. This article aims at reviewing the existing research effort in the rapidly growing field related to the development of biomaterial scaffolds and lab-on-a-chip systems for NTE applications. Besides presenting recent advances achieved by NTE strategies, this work also delineates existing limitations and highlights emerging possibilities and future prospects in this field. © 2020 The Authors.Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may have particular utility for that indication. We report here a series of ten such adult patients treated sequentially at a single center with EMA (cytarabine 500 mg/m2/day as continuous infusion on days 1-3 and days 8-10, mitoxantrone 12 mg/m2/day on days 1-3, and etoposide 200 mg/m2/day as continuous infusion on days 8-10). The overall complete remission rate was 40% (including 3 of 4 of those with relapsed disease) but use of this regimen was associated with prolonged cytopenia and a high rate of infectious adverse events. Even with the availability of modern infectious prophylaxis and therapies, the EMA regimen is likely best reserved for those with relapsed disease treated with curative intent prior to an allogeneic hematopoietic cell transplant.in English, French Les auteurs décrivent le cas d’un homme âgé de 64 ans présentant un syndrome coronarien aigu, une fonction ventriculaire gauche réduite et une triple vasculopathie à l’angiogramme. Le patient a refusé une intervention chirurgicale et a plutôt subi une intervention coronarienne percutanée hautement risquée, réalisée au moyen d’une gaine Impella (Abiomed, Danvers, MA). Il s’agit de l’un des premiers cas connus d’intervention coronarienne percutanée protégée à accès unique, une technique novatrice qui met en lumière l’utilité d’un accès vasculaire double grâce à une gaine Impella.in English, French Après avoir trébuché, une femme âgée de 66 ans est tombée sur ses mains étendues. Son thorax n’a pas touché le sol. Elle a par la suite éprouvé une douleur thoracique et s’est présentée au service des urgences en état de choc. Une échocardiographie transthoracique a révélé un important épanchement péricardique et une tamponnade cardiaque. Malgré des péricardiocentèses répétées, le volume de liquide observé à l’échocardiographie ne diminuait pas et la pa
